WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY

IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis and has limited treatment options. Zigakibart (BION-1301) is a novel, humanized monoclonal antibody that blocks APRIL (a proliferation-inducing ligand), a cytokine that is elevated in patients with IgAN. APRIL promotes the production of pathogenic galactose-deficient IgA1 (Gd-IgA1), resulting in immune complex formation and glomerular deposition, causing inflammation and kidney injury. Blocking APRIL with zigakibart is a potential disease-modifying approach to treating IgAN.